Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE versus ROBINUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE versus ROBINUL.
ATROPINE vs ROBINUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists. Inhibits vagal activity, increases heart rate, reduces secretions, and relaxes smooth muscle.
Antimuscarinic; competitively antagonizes acetylcholine at muscarinic receptors, inhibiting parasympathetic nerve impulses.
0.5-1 mg IV/IM/SC every 3-5 minutes as needed, up to a total of 3 mg (adults). For preoperative use, 0.4-0.6 mg IM/IV 30-60 minutes before anesthesia.
1-2 mg orally 3-4 times daily; 0.1-0.2 mg intramuscular or intravenous every 6-8 hours as needed.
None Documented
None Documented
2-4 hours (terminal); prolonged in elderly and neonates; clinically requires dosing every 4-6 hours
Clinical Note
moderateBenzatropine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Dronedarone
Terminal elimination half-life is approximately 3–4 hours in healthy adults; in elderly or patients with renal impairment, half-life may be prolonged (up to 10 hours). Clinical context: Steady-state achieved within 24 hours; clinically insignificant accumulation with repeated dosing every 4–6 hours.
Renal (30-50% unchanged; remainder as inactive metabolites via hydrolysis and glucuronidation); 50-70% of a dose renally excreted as metabolites; <5% fecal
Biliary/fecal elimination is the primary route (approximately 80-85% of a dose is recovered in feces as unchanged drug and metabolites); renal excretion accounts for ~15-20% (mostly unchanged drug and active metabolite).
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent
"The metabolism of Dronedarone can be decreased when combined with Benzatropine."